Pacira BioSciences (PCRX) Inventory Average (2011 - 2026)

Pacira BioSciences' Inventory Average history runs 16 years deep, the most recent figure standing at $151.6 million for Q1 2026.

• On a quarterly basis, Inventory Average rose 17.06% year-over-year to $151.6 million in Q1 2026; TTM through Mar 2026 was $151.6 million, a 17.06% increase from a year earlier, with the FY2025 full-year figure at $139.1 million, up 21.12% from the prior year.
• Inventory Average fell to $151.6 million in Q1 2026 per PCRX's latest filing, from $155.3 million in the prior quarter.
• Across five years, Inventory Average topped out at $155.3 million in Q4 2025 and bottomed at $92.6 million in Q2 2023.
• The 5-year median for Inventory Average is $101.1 million (2022), against an average of $114.0 million.
• Across the five-year window, Inventory Average soared 57.27% in 2022 and declined 9.37% in 2023, its largest moves.
• Year by year, Inventory Average stood at $96.4 million in 2022, then grew by 4.15% to $100.4 million in 2023, then rose by 18.06% to $118.6 million in 2024, then surged by 30.95% to $155.3 million in 2025, then declined by 2.35% to $151.6 million in 2026.
• Per Business Quant, the three latest PCRX Inventory Average figures stand at $151.6 million (Q1 2026), $155.3 million (Q4 2025), and $152.9 million (Q3 2025).